Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a publicly traded Healthcare sector company. As of May 21, 2026, CVKD trades at $5.32 with a market cap of $14.84M and a P/E ratio of -0.78. CVKD moved +0.00% today. Year to date, CVKD is -29.51%; over the trailing twelve months it is -67.09%. Its 52-week range spans $4.21 to $22.90. Analyst consensus is buy with an average price target of $29.00. Rallies surfaces CVKD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cadrenal’s CAD-1005 Improves Glycemic Control in Obesity Models, Reduces HIT Thrombotic Events: Cadrenal Therapeutics highlighted preclinical data showing oral CAD-1005 improved glycemic control, reduced pancreatic β-cell loss and inflammatory cell infiltration in adipose and pancreatic tissues in obesity and Type 2 diabetes models. Phase 2 trial of CAD-1005 for suspected HIT showed a reduction in thrombotic events.
| Metric | Value |
|---|---|
| Price | $5.32 |
| Market Cap | $14.84M |
| P/E Ratio | -0.78 |
| EPS | $-6.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.90 |
| 52-Week Low | $4.21 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.24M |
| Gross Margin | 0.00% |
2 analysts cover CVKD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.00.